Key Takeaways
Alpha Cognition (NASDAQ: ACOG) reported first-quarter net product revenue of $3.5 million, a 40% sequential increase, as its Alzheimer's treatment Zunveyl gained commercial traction.
"We delivered 40% sequential revenue growth from Q4 to Q1, supported by clear quarter-over-quarter acceleration in prescriber adoption," Michael McFadden, Chief Executive Officer of Alpha Cognition, said in a statement.
The company dispensed 6,054 bottles of Zunveyl, a 23% increase from the fourth quarter, and grew its active prescriber base by 23% to 1,060 healthcare providers. The company reported a net loss of $6.5 million, or $0.30 per share, and ended the quarter with $54.2 million in cash.
Alpha Cognition reiterated its goal to achieve operating profitability in 2027. Investors are watching for top-line data from the BEACON study in early Q3 2026, which the company expects will support broader payer coverage for Zunveyl.
The results mark the fourth full quarter of commercialization for Zunveyl. Chief Operating Officer Lauren D’Angelo said the company saw “meaningful execution across prescriber adoption, nursing home penetration, and payer engagement.”
The number of long-term care homes with Zunveyl prescriptions increased 25% from the prior quarter to 914. Repeat prescriptions were a key theme, with 75% of active writers and 81% of long-term care facilities placing repeat orders. The company also implemented a 6% price increase for Zunveyl during the quarter, bringing the list price to $869.36.
Total operating expenses for the first quarter were $11.6 million, up from $10.7 million in the fourth quarter of 2025. The company attributed the increased spending to investments in its commercial infrastructure and the initiation of clinical studies.
Alpha Cognition reaffirmed its full-year 2026 operating expense guidance of $54 million to $58 million. The company maintains a debt-free balance sheet and stated its current cash position is sufficient to fund operations as it targets profitability in 2027.
The company provided updates on three real-world studies intended to strengthen Zunveyl's position with payers and providers. Enrollment for the BEACON study is complete, with top-line data now expected in early Q3 2026, an acceleration from the previous Q4 timeline.
A retrospective study, CONVERGE, initiated in April with data expected in the third quarter of 2026. A Phase IV outpatient study, RESOLVE, is expected to begin in the second quarter of 2026 and complete in the second quarter of 2027.
The U.S. Patent Office also issued two new patents for Zunveyl, extending protection through 2045 and covering its use for treating traumatic brain injury, a market the company estimates at $14 billion.
The accelerated BEACON data readout provides a significant near-term event for the company. Positive results could be a key factor in expanding payer access, which management identified as its "most significant near-term opportunity." Investors will be watching for the data in Q3, followed by updates on the CONVERGE study.
This article is for informational purposes only and does not constitute investment advice.
